Source: CTD Holdings, Inc. 7/18/19
CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company
that develops cyclodextrin-based products for the treatment of disease
with unmet medical need, today announced that the Company’s Scientific
Advisory Board endorsed Alzheimer’s Disease as the company’s next drug
development indication. The Scientific Advisory Board met via
videoconference on July 17, 2019. The endorsement was made based on the
company’s data from an ongoing expanded access program in late-onset
Alzheimer’s Disease with Trappsol® Cyclo™ and on data from two ongoing trials using Trappsol®
Cyclo™ in Niemann-Pick Disease Type C, a rare genetic disease which may
also lead to cognitive decline. The expanded access program in
late-onset Alzheimer’s Disease is now in its second year. CTD’s
Niemann-Pick Disease Type C trials and the expanded access program in
Alzheimer’s are based on intravenous administration of the drug.
CTD Chairman and CEO N. Scott Fine said, “CTD is grateful to the
Scientific Advisory Board for its insights and its work. We will move
forward to build and launch a clinical trial in Alzheimer’s Disease.”
The Scientific Advisory Board is led by two Co-Chairs: Rita Colwell,
PhD, Distinguished University Professor both at the University of
Maryland at College Park and at Johns Hopkins University Bloomberg
School of Public Health, and former Director of the National Science
Foundation, and Sharon Hrynkow, PhD, CTD’s Chief Scientific Officer and
Senior Vice President for Medical Affairs.
Scientific Advisory Board members are:
M. Flint Beal, MD, University Professor of Neurology and Neuroscience in
the Department of Neurology and Neuroscience at the Weill Medical
College of Cornell University - New York Presbyterian Hospital;
Caroline Hastings, MD, Pediatric Hematologist/Oncologist and senior
clinician-scientist and educator at the UCSF Benioff Children’s
Hospital, Oakland CA; and
Benny Liu, MD, Associate Division Chief of Gastroenterology at Highland
Hospital in Oakland, CA and an Assistant Clinical Professor at the
University of California, San Francisco (UCSF).
The Scientific Advisory Board plans to meet in late 2019 to consider additional future drug development indications.
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that
develops cyclodextrin-based products for the treatment of disease. The
company’s Trappsol® Cyclo™, an orphan drug designated product
in the United States and Europe, is used to treat Niemann-Pick Disease
Type C, a rare and fatal genetic disease, on a compassionate use basis
as well as in three ongoing formal clinical trials (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.ctd-holdings.com
No comments:
Post a Comment